Raymond Tesi
Chief Executive Officer at INMUNE BIO, INC.
Net worth: 15 M $ as of 31/05/2024
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Lindsay Rosenwald | M | 68 | 15 years | |
Ray Takigiku | M | - |
Bexion Pharmaceuticals, Inc.
Bexion Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Bexion Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of oncology treatments. The firm is developing BXQ-350, a first-in-class agent composed of the multifunctional, lysosomal activator protein Saposin C and phosphatidylserine. The company was founded by Ray Takigiku in 2006 and is headquartered in Covington, KY. | 18 years |
David Moss | M | 54 | 9 years | |
Mark Lowdell | M | 61 | 9 years | |
Scott R. Shively | M | 67 |
Bexion Pharmaceuticals, Inc.
Bexion Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Bexion Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of oncology treatments. The firm is developing BXQ-350, a first-in-class agent composed of the multifunctional, lysosomal activator protein Saposin C and phosphatidylserine. The company was founded by Ray Takigiku in 2006 and is headquartered in Covington, KY. | - |
Timothy Schroeder | M | 66 |
Bexion Pharmaceuticals, Inc.
Bexion Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Bexion Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of oncology treatments. The firm is developing BXQ-350, a first-in-class agent composed of the multifunctional, lysosomal activator protein Saposin C and phosphatidylserine. The company was founded by Ray Takigiku in 2006 and is headquartered in Covington, KY. | 8 years |
Scott Juda | M | 53 | 6 years | |
Edgardo Baracchini | M | 64 | 5 years | |
J. Ganjei | M | 50 | 8 years | |
Marcia Allen | F | 73 | 5 years | |
Jimmie Harvey | M | 72 | 16 years | |
Scott M. Freeman | M | 67 |
Savant HWP, Inc.
Savant HWP, Inc. Pharmaceuticals: MajorHealth Technology Savant HWP, Inc. develops and manufactures pharmaceutical products. The American company was founded by Stephen Hurst. | - |
Keith A Carlson | M | - |
Bexion Pharmaceuticals, Inc.
Bexion Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Bexion Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of oncology treatments. The firm is developing BXQ-350, a first-in-class agent composed of the multifunctional, lysosomal activator protein Saposin C and phosphatidylserine. The company was founded by Ray Takigiku in 2006 and is headquartered in Covington, KY. | - |
Chuck Scheper | M | - |
Bexion Pharmaceuticals, Inc.
Bexion Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Bexion Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of oncology treatments. The firm is developing BXQ-350, a first-in-class agent composed of the multifunctional, lysosomal activator protein Saposin C and phosphatidylserine. The company was founded by Ray Takigiku in 2006 and is headquartered in Covington, KY. | - |
Joshua S. Schoonover | M | - | - | |
Margaret M. van Gilse | F | - |
Bexion Pharmaceuticals, Inc.
Bexion Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Bexion Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of oncology treatments. The firm is developing BXQ-350, a first-in-class agent composed of the multifunctional, lysosomal activator protein Saposin C and phosphatidylserine. The company was founded by Ray Takigiku in 2006 and is headquartered in Covington, KY. | - |
Catherine Pearce | F | - |
Bexion Pharmaceuticals, Inc.
Bexion Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Bexion Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of oncology treatments. The firm is developing BXQ-350, a first-in-class agent composed of the multifunctional, lysosomal activator protein Saposin C and phosphatidylserine. The company was founded by Ray Takigiku in 2006 and is headquartered in Covington, KY. | 1 years |
Jim Beach | M | - |
Bexion Pharmaceuticals, Inc.
Bexion Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Bexion Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of oncology treatments. The firm is developing BXQ-350, a first-in-class agent composed of the multifunctional, lysosomal activator protein Saposin C and phosphatidylserine. The company was founded by Ray Takigiku in 2006 and is headquartered in Covington, KY. | - |
Olivia Kirtley | F | 74 |
Bexion Pharmaceuticals, Inc.
Bexion Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Bexion Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of oncology treatments. The firm is developing BXQ-350, a first-in-class agent composed of the multifunctional, lysosomal activator protein Saposin C and phosphatidylserine. The company was founded by Ray Takigiku in 2006 and is headquartered in Covington, KY. | 3 years |
Cameron Durrant | M | 63 |
Bexion Pharmaceuticals, Inc.
Bexion Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Bexion Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of oncology treatments. The firm is developing BXQ-350, a first-in-class agent composed of the multifunctional, lysosomal activator protein Saposin C and phosphatidylserine. The company was founded by Ray Takigiku in 2006 and is headquartered in Covington, KY. | - |
Tara Lehner | F | - | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Richard Shively | M | - |
Bexion Pharmaceuticals, Inc.
Bexion Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Bexion Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of oncology treatments. The firm is developing BXQ-350, a first-in-class agent composed of the multifunctional, lysosomal activator protein Saposin C and phosphatidylserine. The company was founded by Ray Takigiku in 2006 and is headquartered in Covington, KY. | - |
Glenn L. Cooper | M | 71 | 4 years | |
Stephen Hurst | M | - |
Savant HWP, Inc.
Savant HWP, Inc. Pharmaceuticals: MajorHealth Technology Savant HWP, Inc. develops and manufactures pharmaceutical products. The American company was founded by Stephen Hurst. | 10 years |
James Breitmeyer | M | 70 |
Washington University School of Medicine
| 3 years |
Raju Narasa R. Mantena | M | 79 |
Washington University School of Medicine
| 2 years |
Michael Apkon | M | 64 |
Washington University School of Medicine
| 7 years |
David Szymkowski | M | 60 | 3 years | |
Wozniak Gregory T. | M | - |
Washington University School of Medicine
| 3 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 29 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Raymond Tesi
- Personal Network